BioXcel Therapeutics Profit Margin

BioXcel Therapeutics (BTAI) currently reports a profit margin of -9549.87% as of June 2026. That compares with -5869.82% in the prior-year period — down 62.7% year over year. That is below the Healthcare sector average of 13.45%. Use the charts on this page to explore BioXcel Therapeutics's profit margin history and peer comparisons.

BioXcel Therapeutics's profit margin decreased from -5869.82% to -9549.87% — a 62.7% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

BioXcel Therapeutics's profit margin of -9549.87% is lower than the Healthcare sector average of 13.45%. That is roughly 71114.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but BioXcel Therapeutics's current -9549.87% should be judged against Healthcare norms (sector average: 13.45%) and against BTAI's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -9549.87%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.45%. From there, open related valuation or income-statement pages for BioXcel Therapeutics, and consider following BTAI for alerts when major investors trade the stock.